References
- Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015;30:934–44
- Kanis JA, McCloskey E, Johansson VH, et al. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). Osteoporos Int 2013;24:23–57
- de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
- Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One 2013;8:e78016
- Simon JA. What if the Women’s Health Initiative had used transdermal estradiol and oral progesterone instead? Menopause 2014;21:769–83
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
- Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44–7
- Li L, Roddam A, Gitlin M, et al. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause 2012;19: 33–40
- Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356: 1809–22
- Lee YK, Nho JH, Ha YC, Koo KH. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 2012;23:2329–33
- Hadji P, Papaioannou NA, Gielen E, et al. 12-Month persistence with denosumab in women with postmenopausal osteoporosis: interim results of a 24-month prospective observational study in Germany, Austria, Greece and Belgium. Presented at WCO-IOF-ESCEO, Seville, Spain; April 2–5, 2014, Poster Nr. P150
- Boschitsch E, Trinker N. Persistence with denosumab in a menopause and osteoporosis clinic. Presented at ECTS-IBMS 2015 Congress, Rotterdam, The Netherlands; April 25–28, 2015, Poster Nr. P357
- Papapoulos S, Lippuner K, Roux C, et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM Extension. Presented at ASBMR, Baltimore, USA; October 4–7, 2013, presentation number: LB-MO26
- Papapoulos S, Roux C, Bone HG, et al. Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the FREEEDOM extension. Presented at WCO-IOF-ESCEO, Milan, Italy; March 27, 2015, OC4
- Pazianas M, Cooper C, Ebetino FH, et al. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;6:325–43
- Baron R, Ferrari S, Russell RG. Denosumab and BPs: different mechanisms of action and effects. Bone 2011;48:677–92